Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... BETHESDA, Md., Nov. 1, 2011   For the first ... cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review ... approval in 2012. This milestone comes as the largest ... Anaheim, Calif., Nov. 3 – 5, 2011. ...
... the world,s leading provider of centralized expert assessments in ... disorders, announced it has been selected as one of ... NJBIZ, New Jersey,s premiere business news publication, annually identifies ... New Jersey,s most dynamic companies who progressively contribute to ...
Cached Medicine Technology:Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care 2MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... Newport Beach, CA (PRWEB) November 23, 2014 ... founder of American Medical Aesthetics & Wellness was ... Dr. Asher Milgrom, Ph.D. is president and CEO of ... Skincare. Dr. Asher Milgrom received a full scholarship ... Sciences and the Medical School at the University of ...
(Date:11/23/2014)... Syngenta lawsuits are now being investigated ... and agribusinesses that have allegedly incurred significant financial damages ... and Agrisure Duracade, genetically modified (GMO) corn seed ... in China. According to a report from Bloomberg News, ... corn imports. Because China is the third-largest American corn ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3
... of using plant hormones to fight cancer cells. Plant need ... cuttings grow roots. Scientists at the Cancer Research Campaign (CRC), ... kill cancer cells. , Indole ... IAA are added with an enzyme, toxic by products, which ...
... itself by growing new cells after a heart attack. This ... Italy. Dr. Piero Anversa and colleagues of the New York ... called myocytes continued to divide after a heart attack. ... the hearts of 13 people who died within a few ...
... disease, that requires insulin injections daily. Researchers are slowly ... Some medical research centers in the U.S. and Europe ... by transplanting insulin-producing islet cells combined with less toxic ... lives without insulin. , A.M. ...
... size of children's tummies may offer a simple method of ... diabetes at a later age.Among adults, fat around the waist ... studies suggest that it is a better indicator of risk ... ,A large waist is said to be associated ...
... the brain and its function has always left man ... puzzle, some key factors// have been identified that could ... in premature babies and hence help treat prematurity. ... also prevent brain damage repair in neurological diseases like ...
... drinking coffee could decrease the risk of liver cancer.Researchers ... showed self-reported frequency of coffee consumption among more than ... researchers say they found that those who drink coffee ... while those drinking one or more cups a day ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
Nucleus chopper. For bimanual nucleus division....
Phaco chopper, a combination of a Sinskey hook and a pointed "quick chop" tip....
Phaco prechopper with blunt tip double-edge for bi-directional prechopping. For bimanual nucleus prechopping technique....
Titanium. A reverse action instrument with a paddle tips to provide a solid surface to crack the nucleus. When used in scleral tunnel, the reverse action mechanism allows increased flexibility in pos...
Medicine Products: